Small molecule allosteric modulators of phosphodiesterase 4

Handbook of Experimental Pharmacology

Volumn 204, Issue , 2011, Pages 167-192

  Gurney, Mark E ^a   Burgin, Alex B ^b   Magnusson, Olafur T ^c   Stewart, Lance J ^b  

^a Tetra Discovery Partners   (United States)

^b Emerald BioStructures   (United States)

^c DECODE GENETICS   (Iceland)

Author keywords

Accessory Proteins; Active Site; Asymmetric Conformer; PDE4 Gating; Phosphodiesterase 4 (PDE4)

Indexed keywords

CILOMILAST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; D 159687; GLYCINE; ISOLEUCINE; LEUCINE; LEUKOTRIENE E4; MYOMEGALIN; PHENYLALANINE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV D5; PHOSPHODIESTERASE IV INHIBITOR; RECEPTOR FOR ACTIVATED C KINASE 1; REGULATOR PROTEIN; ROFLUMILAST; ROLIPRAM; RS 25344; STEROID; SYNTHETIC PEPTIDE PMNPQ; UNCLASSIFIED DRUG; UPSTREAM CONSERVED REGION 1; UPSTREAM CONSERVED REGION 2;

AMINO TERMINAL SEQUENCE; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHANNEL GATING; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DEPRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GENE CONSTRUCT; HUMAN; HYDROPHOBICITY; IC 50; LONG TERM MEMORY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DOMAIN; RESPIRATORY TRACT DISEASE; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; VOMITING; ALLOSTERISM; AMINO ACID SEQUENCE; ANIMAL; BINDING SITE; CHEMISTRY; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; REVIEW;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE 4 INHIBITORS; PROTEIN STRUCTURE, TERTIARY;

EID: 79960905739     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17969-3_7     Document Type: Article

References (102)

1. Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T (2001) Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 298:1142-1149 (Pubitemid 32761931)
2. Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, Carr DW (2004) A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines. J Immunol 173:4806-4814 (Pubitemid 39387760)
3. Bailey CH, Bartsch D, Kandel ER (1996) Toward a molecular definition of long-term memory storage. Proc Natl Acad Sci U S A 93:13445-13452 (Pubitemid 26424140)
4. Baillie GS, Adams DR, Bhari N, Houslay TM, Vadrevu S, Meng D, Li X, Dunlop A, Milligan G, Bolger GB, Klussmann E, Houslay MD (2007) Mapping binding sites for the PDE4D5 cAMPspecific phosphodiesterase to the N-and C-domains of beta-arrestin using spot-immobilized peptide arrays. Biochem J 404:71-80 (Pubitemid 46788086)
5. Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, Bolger GB (2000) UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem 275:10349-10358 (Pubitemid 30202094)
6. Blackwood DH, Muir WJ (2004) Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. Neurotox Res 6:35-41
7. Blokland A, Schreiber R, Prickaerts J (2006) Improving memory: a role for phosphodiesterases. Curr Pharm Des 12:2511-2523
8. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastrey-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H (1988) Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238:2-6 (Pubitemid 19008259)
9. Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, Riggs M, Wigler M, Ferguson K (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13:6558-6571 (Pubitemid 23292650)
10. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, Houslay MD(2003a) The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem 278:49230-49238
11. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS, Houslay MD (2003b) Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. J Biol Chem 278:33351-33363 (Pubitemid 37055787)
12. Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A, Mitchell LH, McCahill A, Hundsrucker C, Klussmann E, Adams DR, Houslay MD (2006) Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J 398:23-36 (Pubitemid 44231298)
13. Brideau C, Van Staden C, Styhler A, Rodger IW, Chan CC (1999) The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. Br J Pharmacol 126:979-988 (Pubitemid 29103714)
14. Burgin AB, Magnusson OT, Singh J, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Witte P, Staker BL, Kiselyov AS, Stewart LJ, Gurney ME (2010) Design of Phosphodiesterase Type 4D (PDE4D) allosteric modulators for cognition with improved safety. Nat Biotechnol 28:63-70
15. Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 12:2233-2247 (Pubitemid 39593200)
16. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD (2004) PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J 381:587-592 (Pubitemid 39120466)
17. Castro LR, Gervasi N, Guiot E, Cavellini L, Nikolaev VO, Paupardin-Tritsch D, Vincent P (2010) Type 4 phosphodiesterase plays different integrating roles in different cellular domains in pyramidal cortical neurons. J Neurosci 30:6143-6151
18. Chambers RJ, Abrams K, Castleberry TA, Cheng JB, Fisher DA, Kamath AV, Marfat A, Nettleton DO, Pillar JD, Salter ED, Sheils AL, Shirley JT, Turner CR, Umland JP, Lam KT (2006) A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function. Bioorg Med Chem Lett 16:718-721 (Pubitemid 43014867)
19. Charlie NK, Thomure AM, Schade MA, Miller KG (2006) The Dunce cAMP phosphodiesterase PDE-4 negatively regulates G alpha(s)-dependent and G alpha(s)-independent cAMP pools in the Caenorhabditis elegans synaptic signaling network. Genetics 173:111-130 (Pubitemid 43800188)
20. Chen CN, Denome S, Davis RL (1986) Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dunce + gene, the structural gene for cAMP phosphodiesterase. Proc Natl Acad Sci U S A 83:9313-9317 (Pubitemid 17223351)
21. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, Kaneda H, Shiroishi T, Houslay MD, Henkelman RM, Sled JG, Gondo Y, Porteous DJ, Roder JC (2007) Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54:387-402 (Pubitemid 46671409)
22. Conti M, Iona S, Cuomo M, Swinnen JV, Odeh J, Svoboda ME (1995) Characterization of a hormone-inducible, high affinity adenosine 30-50-cyclic monophosphate phosphodiesterase from the rat Sertoli cell. Biochemistry 34:7979-7987
23. Cooper DM (2003) Regulation and organization of adenylyl cyclases and cAMP. Biochem J 375:517-529 (Pubitemid 37433500)
24. Davis RL, Takayasu H, Eberwine M, Myres J (1989) Cloning and characterization of mammalian homologs of the Drosophila dunce + gene. Proc Natl Acad Sci U S A 86:3604-3608
25. Day JP, Dow JA, Houslay MD, Davies SA (2005) Cyclic nucleotide phosphodiesterases in Drosophila melanogaster. Biochem J 388:333-342 (Pubitemid 40732962)
26. DeMarch Z, Giampà C, Patassini S, Bernardi G, Fusco FR (2008) Beneficial effects of rolipram in the R6/2 mouse model of Huntingtons disease. Neurobiol Dis. Jun;30(3):375-387 Epub 2008 Mar 7. PMID:18424161
27. Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Berner P, Simhandl C, Wolf R, Gerlach W, Jaklitsch H, Sastre-Hernandez M et al (1992) A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 26:59-64
28. Fujimaki K, Morinobu S, Duman RS (2000) Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 22:42-51
29. Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57:48-64 (Pubitemid 34873742)
30. Giembycz MA (2005) Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:326-333, discussion 340-321 (Pubitemid 41566944)
31. Giembycz MA (2006) An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 62:138-152 (Pubitemid 44316425)
32. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624-1634 (Pubitemid 40385553)
33. Hatzelmann A, Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279 (Pubitemid 32242587)
34. Heaslip RJ, Evans DY (1995) Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 286:281-290
35. Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, Sastre-Hernandez M, Schony W, Schratzer M, SoukopWet al (1989) Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22:156-160 (Pubitemid 19176094)
36. Henkel-Tigges J, Davis RL (1990) Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724. Mol Pharmacol 37:7-10 (Pubitemid 20038442)
37. Hirose R, Manabe H, Nonaka H, Yanagawa K, Akuta K, Sato S, Ohshima E, Ichimura M (2007) Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. Eur J Pharmacol 573:93-99 (Pubitemid 47464209)
38. Hoffmann R, Wilkinson IR, McCallum JF, Engels P, Houslay MD (1998) cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 333(Pt 1):139-149 (Pubitemid 28342503)
39. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 18:893-903 (Pubitemid 29082269)
40. Houslay MD (2001) PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69:249-315 (Pubitemid 33805840)
41. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18 (Pubitemid 36259414)
42. Houslay MD, Adams DR (2010) Putting the lid on phosphodiesterase 4. Nat Biotechnol 28:38-40
43. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519 (Pubitemid 41527193)
44. Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100:950-966 (Pubitemid 46598920)
45. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, Houslay MD (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344 (Pubitemid 26408583)
46. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899 (Pubitemid 26347710)
47. Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99:7628-7633 (Pubitemid 34568742)
48. Jin SL, Richard FJ, Kuo WP, D Ercole AJ, Conti M(1999) Impaired growth and fertility of cAMPspecific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 96:11998-12003 (Pubitemid 29502847)
49. Ke H, Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403 (Pubitemid 46358652)
50. Kovala T, Sanwal BD, Ball EH (1997) Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants. Biochemistry 36:2968-2976 (Pubitemid 27138581)
51. Kranz M, Wall M, Evans B, Miah A, Ballantine S, Delves C, Dombroski B, Gross J, Schneck J, Villa JP, Neu M, Somers DO (2009) Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorg Med Chem 17:5336-5341
52. Laux G, Becker T, Kuhne G, Lesch KP, Riederer P, Beckmann H (1988) Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level. Pharmacopsychiatry 21:378-379 (Pubitemid 19024190)
53. Lee ME, Markowitz J, Lee JO, Lee H (2002) Crystal structure of phosphodiesterase 4D and inhibitor complex(1). FEBS Lett 530:53-58 (Pubitemid 35248185)
54. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25-35 (Pubitemid 41414526)
55. Li YF, Huang Y, Amsdell SL, Xiao L, ODonnell JM, Zhang HT (2009) Antidepressant-and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 34:2404-2419
56. Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167-175 (Pubitemid 40091808)
57. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, Huang Z (2001) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40:10179-10186 (Pubitemid 32800124)
58. Lorimer D, Raymond A, Walchli J, Mixon M, Wallace E, Barrow A, Grice R, Burgin A, Stewart L (2009) Gene composer: database software for protein construct design, codon engineering, and gene synthesis. BMC Biotechnol 9:36
59. Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398 (Pubitemid 43132818)
60. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280:33178-33189 (Pubitemid 41397113)
61. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD (2000) ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 275:16609-16617 (Pubitemid 30398887)
62. McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, Ross AH, Houslay ES, Houslay MD (1999) Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J Biol Chem 274:11796-11810
63. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310:1187-1191 (Pubitemid 41681745)
64. Monaco L, Vicini E, Conti M (1994) Structure of two rat genes coding for closely related rolipramsensitive cAMP phosphodiesterases. Multiple mRNA variants originate from alternative splicing and multiple start sites. J Biol Chem 269:347-357
65. Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E, Porteous DJ, Millar JK, Houslay MD (2007) Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci 27:9513-9524 (Pubitemid 47358203)
66. Naganuma K, Omura A, Maekawara N, Saitoh M, Ohkawa N, Kubota T, Nagumo H, Kodama T, Takemura M, Ohtsuka Y, Nakamura J, Tsujita R, Kawasaki K, Yokoi H, Kawanishi M (2009) Discovery of selective PDE4B inhibitors. Bioorg Med Chem Lett 19:3174-3176
67. Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS (2009) Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci U S A 106:18225-18230
68. Perez-Torres S, Miro X, Palacios JM, Cortes R, Puigdomenech P, Mengod G (2000) Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3 H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20:349-374 (Pubitemid 32162892)
69. Raymond A, Lovell S, Lorimer D, Walchli J, Mixon M, Wallace E, Thompkins K, Archer K, Burgin A, Stewart L (2009) Combined protein construct and synthetic gene engineering for heterologous protein expression and crystallization using Gene Composer. BMC Biotechnol 9:37
70. Reid P (2002) Roflumilast Altana Pharma. Curr Opin Investig Drugs 3:1165-1170 (Pubitemid 36266768)
71. Richter W, Conti M (2002) Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs). J Biol Chem 277:40212-40221 (Pubitemid 35215591)
72. Robichaud A, Tattersall FD, Choudhury I, Rodger IW (1999) Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38:289-297 (Pubitemid 29073550)
73. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40:262-269
74. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC (2002a) Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135:113-118 (Pubitemid 34102104)
75. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC (2002b) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110:1045-1052
76. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, Hoffman CR, Luther MA (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 36:14250-14261 (Pubitemid 27509861)
77. Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L, Callan O, Su C, Jarnagin K, Shelton ER (1998) Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal 10:427-440 (Pubitemid 28327510)
78. Scott AI, Perini AF, Shering PA, Whalley LJ (1991) In-patient major depression: is rolipram as effective as amitriptyline? Eur J Clin Pharmacol 40:127-129
79. Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534 (Pubitemid 26239006)
80. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M (2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106:16877-16882
81. Souness JE, Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236 (Pubitemid 27271642)
82. Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308-315
83. Stefan E, Wiesner B, Baillie GS, Mollajew R, Henn V, Lorenz D, Furkert J, Santamaria K, Nedvetsky P, Hundsrucker C, Beyermann M, Krause E, Pohl P, Gall I, MacIntyre AN, Bachmann S, Houslay MD, Rosenthal W, Klussmann E (2007) Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. J Am Soc Nephrol 18:199-212 (Pubitemid 46053433)
84. Swinnen JV, Joseph DR, Conti M (1989) Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci U S A 86:5325-5329 (Pubitemid 19185546)
85. Terrenoire C, Houslay MD, Baillie GS, Kass RS (2009) The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4D3. J Biol Chem 284: 9140-9146
86. Terrin A, Di Benedetto G, Pertegato V, Cheung YF, Baillie G, Lynch MJ, Elvassore N, Prinz A, Herberg FW, Houslay MD, Zaccolo M (2006) PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol 175:441-451 (Pubitemid 44708068)
87. Tully T, Bourtchouladze R, Scott R, Tallman J (2003) Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov 2:267-277 (Pubitemid 37361685)
88. Ueno S, Matsuki N, Saito H (1987) Suncus murinus: a new experimental model in emesis research. Life Sci 41:513-518 (Pubitemid 17105232)
89. Vecsey CG, Baillie GS, Jaganath D, Havekes R, Daniels A, Wimmer M, Huang T, Brown KM, Li XY, Descalzi G, Kim SS, Chen T, Shang YZ, Zhuo M, Houslay MD, Abel T (2009) Sleep deprivation impairs cAMP signalling in the hippocampus. Nature 461:1122-1125
90. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SL, Conti M (2001) Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276:11189-11198 (Pubitemid 38089303)
91. Wachtel H (1983) Potential antidepressant activity of rolipram and other selective cyclic adenosine 30, 50-monophosphate phosphodiesterase inhibitors. Neuropharmacology 22:267-272 (Pubitemid 13144221)
92. Wang H, Peng MS, Chen Y, Geng J, Robinson H, Houslay MD, Cai J, Ke H (2007a) Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J 408:193-201 (Pubitemid 350206342)
93. Wang H, Robinson H, Ke H (2007b) The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J Mol Biol 371:302-307 (Pubitemid 47048279)
94. Warrier S, Ramamurthy G, Eckert RL, Nikolaev VO, Lohse MJ, Harvey RD (2007) cAMP microdomains and L-type Ca2+ channel regulation in guinea-pig ventricular myocytes. J Physiol 580:765-776 (Pubitemid 46909033)
95. Wilhelm RS, Axt S (1995) 8-phenylcyclopentenoquinoline and 8-phenylcyclohexeneoquinoline derivatives. Syntex, Palo Alto, CA
96. Willoughby D, Wong W, Schaack J, Scott JD, Cooper DM (2006) An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J 25:2051-2061
97. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288:1822-1825 (Pubitemid 30399019)
98. Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917
99. Zeller E, Stief HJ, Pflug B, Sastre-Hernandez M (1984) Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17:188-190 (Pubitemid 15213947)
100. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279-286 (Pubitemid 38950974)
101. Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, Rose GM, ODonnell JM (2006) Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats. Psychopharmacology (Berl) 186:209-217 (Pubitemid 43727338)
102. Zhao Y, Zhang HT, ODonnell JM (2003) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3 H]piclamilast and [3 H]rolipram. J Pharmacol Exp Ther 305:565-572 (Pubitemid 36459171)